Review Article
Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury
Table 2
The biological characteristics of H2S-releasing hybrid drugs.
| Compounds | Parent drugs | Therapeutic effects | References |
| ACS2 | Valproic acid | Anticancer | [116] | Antiangiogenesis | [117] |
| ACS6 | Sildenafil | Proerectile | [118] | Neuroprotection | [119] | Protection against oxidative stress | [120] |
| ACS14 | Aspirin | Protection against oxidative stress | [121] | Prevent the progression of atherosclerosis | [122] | Antiaggregatory | [123] | Protection against I/R injury | [124] | Modulation of thiol homeostasis | [125] | Neuroprotection | [115] |
| ACS15* | Diclofenac | Anticancer | [126] | Antiosteolysis | [127] | Anti-inflammation | [128] | Antiangiogenesis | [117] |
| ACS18 | Sulindac | Anticancer | [126] | Antiangiogenesis | [117] |
| ACS21 | Salicylic acid | Protection against I/R injury | [124] |
| ACS32 | Diclofenac | Antiosteolysis | [127] |
| ACS33 | Valproic acid | Anticancer | [129] | Inhibition of histone deacetylase activity | [129] |
| ACS67 | Latanoprost | Regulation of insulin secretion | [114] | Neuroprotection | [85] |
| ACS83 | L-DOPA | Anti-inflammation | [130] |
| ACS84 | L-DOPA | Anti-inflammation | [131] | Neuroprotection | [132] |
| ACS85 | L-DOPA | Anti-inflammation | [118] |
| ACS86 | L-DOPA | Anti-inflammation | [118] |
| ATB-284 | Unknown | Prevention against irritable bowel syndrome | [133] |
| ATB-337* | Diclofenac | Anti-inflammation | [134] |
| ATB-343 | Indomethacin | Anti-inflammation | [135] |
| ATB-345 | Naproxen | Anti-inflammation | [136] |
| ATB-346 | Naproxen | Anti-inflammation | [136] | Anticancer | [137] |
| ATB-429 | Mesalamine | Anti-inflammation | [138] | Abirritation | [139] |
| HS-aspirin (HS-ASA) | Aspirin | Anticancer | [140] |
| Compound 8e | 3-n-Butylphthalide | Antithrombosis | [141] |
| H2S-EXP 3174 | Active metabolite of losartan | Vasorelaxation | [142] |
| NOSH-aspirin (NBS-1120) | Aspirin | Anticancer | [143] | Anti-inflammation | [144] |
| NOSH-naproxen (AVT-219) | Naproxen | Anti-inflammation | [145] |
| NOSH-sulindac (AVT-18A) | Sulindac | Anti-inflammation | [145] |
| S-diclofenac* | Diclofenac | Anti-inflammation | [146] | Protection against I/R injury | [146] |
| S-zofenopril | Zofenopril | Improvement of vascular function | [147] |
|
|
These compounds are remarkably similar to each other.
|